Download App

Log in to access Online Inquiry
Company Overview More
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
CEO: Goldsmith Ph.D., Mark A.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

RVMD Revolution Medicines

15.890+0.290+1.86%
Close 05/26 20:00 ET
High
16.110
Open
15.700
Turnover
6.14M
Low
15.340
Pre Close
15.600
Volume
386.27K
Market Cap
1.18B
P/E(TTM)
Loss
52wk High
35.070
Shares
74.25M
P/E(Static)
Loss
52wk Low
14.080
Float Cap
858.09M
Bid/Ask %
-33.33%
Historical High
56.180
Shs Float
54.00M
Volume Ratio
0.57
Historical Low
14.080
Dividend TTM
--
Div Yield TTM
--
P/B
2.14
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.71%
Amplitude
4.94%
Avg Price
15.885
Lot Size
1
Float Cap
858.09M
Bid/Ask %
-33.33%
Historical High
56.180
Shs Float
54.00M
Volume Ratio
0.57
Historical Low
14.080
Dividend TTM
--
P/B
2.14
Dividend LFY
--
Turnover Ratio
0.71%
Amplitude
4.94%
Avg Price
15.885
Lot Size
1
Price Forecast

No Data

News

Comment